title: Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
abstract: To test the hypothesis that co-delivery of synergistic drug combinations in the same liposome provides a better anti-tumor effect than the drugs administered in separate liposomes, fluoroorotic acid (FOA) alone and in combination with irinotecan (IRN) were encapsulated in liposomes and evaluated for their anti-tumor activity in the C26 colon carcinoma mouse model. A new chaotropic loading strategy was devised wherein FOA was dissolved in 7 M urea to increase its solubility. This enabled the passive loading of FOA into liposomes at a high concentration. IRN was remote loaded into liposomes that contained the ammonium salt of the multi-valent 1,2,3,4-butanetetracarboxylic acid with a greater than 90% efficiency and at a drug to lipid ratio of 0.2:1. When the two molecules were loaded into the same liposome, FOA was used to remote load IRN. Modulation of the drug/lipid ratio, temperature, and loading time allowed for consistent co-encapsulation of FOA+IRN at various molar ratios. The anti-tumor activity of L-FOA, L-IRN, L-FOA-IRN (5:1), and the L-FOA+L-IRN mixture (5:1) were examined in the C26 mouse model. The maximum tolerated dose of L-FOA was 10 mg/kg given weekly as compared to 100 mg/kg of the non-encapsulated FOA. Delivering two drugs in the same liposome provided a statistically better anti-tumor effect than delivering the drugs in separate liposomes at the same drug ratio. However, the synergistic activity of the 5:1 ratio of free drugs measured on C26 cells in vitro was not observed in the C26 tumor mouse model. These findings point out the challenges to the design of synergistic treatment protocols based upon results from in vitro cytotoxicity studies. L-FOA at 10 mg/kg as a single agent provided the best anti-tumor efficacy which supports previous suggestions that L-FOA has useful properties as a liposome dependent drug.
authors: Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California, San Francisco, California 94143-0912, USA.
authors: Kareen
authors: K
authors: Riviere
authors: Heidi M
authors: HM
authors: Kieler-Ferguson
authors: Katherine
authors: K
authors: Jerger
authors: Francis C
authors: FC
authors: Szoka
references: FEBS Lett. 1985 Jul 22;187(1):73-5
references: 4018256
references: Methods Enzymol. 2005;391:186-99
references: 15721382
references: Pharm Res. 2008 Jul;25(7):1702-13
references: 18320294
references: Cancer Res. 1988 Sep 15;48(18):5237-45
references: 3409248
references: Mol Interv. 2007 Aug;7(4):216-23
references: 17827442
references: Biol Pharm Bull. 2005 May;28(5):822-8
references: 15863886
references: Cancer Res. 1964 Apr;24:513-7
references: 14147828
references: Adv Enzyme Regul. 1984;22:27-55
references: 6382953
references: Clin Cancer Res. 2009 Jan 15;15(2):692-700
references: 19147776
references: Neuro Oncol. 2007 Jan;9(1):20-8
references: 17018695
references: Int J Pharm. 2007 Jun 7;337(1-2):219-28
references: 17270372
references: Biochim Biophys Acta. 2007 Mar;1768(3):678-87
references: 17208196
references: Cancer Res. 1958 Apr;18(3):305-17
references: 13523597
references: Clin Cancer Res. 2004 Jan 15;10(2):728-38
references: 14760096
references: J Pharm Sci. 2008 Nov;97(11):4696-740
references: 18351638
references: Leuk Res. 2009 Jan;33(1):129-39
references: 18676016
references: Cancer Res. 2006 Mar 15;66(6):3271-7
references: 16540680
references: Br J Cancer. 2001 Feb;84(4):579-85
references: 11207057
references: Biochim Biophys Acta. 1995 Dec 13;1240(2):257-65
references: 8541297
references: J Pharm Sci. 2009 Jul;98(7):2540-8
references: 19009594
references: Mol Cancer Ther. 2006 Jul;5(7):1854-63
references: 16891472
references: J Pharmacol Exp Ther. 2001 Sep;298(3):865-72
references: 11504778
references: Int J Cancer. 1993 Jul 30;54(6):959-64
references: 8335404
references: Clin Cancer Res. 2004 Feb 1;10(3):1121-9
references: 14871992
references: Methods Enzymol. 2005;391:71-97
references: 15721375
references: J Pharm Pharm Sci. 2007;10(3):350-7
references: 17727798
references: J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
references: 2359136
references: Pharmacol Rev. 2006 Sep;58(3):621-81
references: 16968952
references: J Control Release. 2009 Oct 1;139(1):73-80
references: 19508880
references: Neuro Oncol. 2007 Oct;9(4):393-403
references: 17652269
references: Invest Ophthalmol Vis Sci. 1987 Aug;28(8):1365-72
references: 3610553
references: Pharmacol Ther. 2000 Aug-Sep;87(2-3):227-53
references: 11008002
references: Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1923-8
references: 526925
references: Mol Cancer Ther. 2009 Aug;8(8):2266-75
references: 19671743
references: Oncol Res. 2007;16(8):361-74
references: 17913044
references: Curr Drug Deliv. 2005 Oct;2(4):341-51
references: 16305437
references: Chemotherapy. 2005 May;51(2-3):93-102
references: 15886469